| アブストラクト | Natalizumab is an alpha4-integrin monoclonal antibody used for treatment of relapsing multiple sclerosis (MS). At least and nearly 30 cases of liver failure in natalizumab-treated patients are listed in the post-marketing FDA adverse event reporting system (FAERS) and twelve patients with severe liver injury, including several after the first infusion, have been reported (Lisotti et al., 2012; Bezabeh et al., 2010; Martinez-Lapiscina et al., 2013; Michael et al., 2007; Hillen et al., 2015). Herein, we describe a case of a young woman with relapsing MS who developed acute liver injury after the second infusion of natalizumab. Liver biopsy demonstrated a mixed pattern of medication-induced injury or partially treated auto-immune hepatitis. Liver function normalized after natalizumab discontinuation and a subsequent liver biopsy showed resolution of hepatitis. The patient's MS has since been successfully treated with rituximab for over a year. We review the published cases of liver injury associated with natalizumab and those in the post-marketing FDA adverse event reporting system (FAERS). |
|---|
| ジャーナル名 | Multiple sclerosis and related disorders |
|---|
| Pubmed追加日 | 2015/11/23 |
|---|
| 投稿者 | Antezana, A; Sigal, S; Herbert, J; Kister, I |
|---|
| 組織名 | Neuromedical Clinic of Central Louisiana, Louisiana, United States.;Division of Gastroenterology, Department of Medicine, NYU School of Medicine, New;York, United States.;Multiple Sclerosis Care Center, Department of Neurology, NYU School of Medicine,;New York, United States. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/26590653/ |
|---|
